Patents by Inventor Zhengshuang XU

Zhengshuang XU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SMALL MOLECULE INHIBITOR AGAINST NASOPHARYNGEAL CARCINOMA, PREPARATION METHOD AND APPLICATION THEREOF
    Publication number: 20240308987
    Abstract: A small molecule inhibitor targeting EB virus antigen protein, and/or a pharmaceutical composition comprising same, capable of being used for treating diseases caused by EB virus infection, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis, especially nasopharyngeal carcinoma. The present disclosure further provides a small molecule inhibitor against nasopharyngeal carcinoma, and/or a pharmaceutical composition comprising same, capable of being used for treating nasopharyngeal carcinoma.
    Type: Application
    Filed: May 15, 2024
    Publication date: September 19, 2024
    Inventors: Zhendong ZHU, Zhengshuang XU, Ting LI, Chao CHE, Xingye REN, Sigui CHEN, Jiayin ZHANG, Ben ZHANG, Qi YANG, Chuanbing ZHANG, Zhen YANG
  • SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF
    Publication number: 20230157996
    Abstract: The present application provides a small-molecule inhibitor targeting an EB virus nuclear antigen protein, and/or a pharmaceutical composition containing the same, which can be used for the treatment of a disease caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present application further provides a small-molecule inhibitor targeting an EB virus nuclear antigen protein, and/or a pharmaceutical composition containing the same, which can be used for the treatment of a disease caused by EBV infection in a lytic and/or latent phase.
    Type: Application
    Filed: December 2, 2022
    Publication date: May 25, 2023
    Applicants: Shenzhen Bay Laboratory, Peking University Shenzhen Graduate School
    Inventors: Zhendong ZHU, Zhengshuang XU, Ting LI, Chao CHE, Qingzhou ZHANG, Sigui CHEN, Huangcan CHEN, Dehu XIANG, Zhen YANG
  • COMPOUND FOR SIMULTANEOUSLY INHIBITING LSD1 AND HDAC TARGETS AND APPLICATION THEREOF
    Publication number: 20200331882
    Abstract: A compound having a general structural formula as shown in Formula I: X-AB-Y (Formula I); in the above Formula I, X is selected from any one of —CO2H, —CONHZ, —CH?CH—CO2H, —CH?CH—CONHZ, wherein Z is selected from any one of substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted aryl, and hydroxyl; Y=—NR1R2, wherein NR1R2 is a substituted or unsubstituted 3- to 9-membered nitrogen-containing heterocycloalkyl; A and B are each independently selected from substituted or unsubstituted phenylene, substituted or unsubstituted azaphenylene. The compound or corresponding pharmaceutical salt thereof can inhibit LSD1 and HDAC target proteins at the same time, thus inhibit the proliferation of many kinds of tumor cells and have good antitumor effect.
    Type: Application
    Filed: July 3, 2020
    Publication date: October 22, 2020
    Applicant: PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL
    Inventors: Junmin QUAN, Qinkai LI, Xin ZENG, Zhengshuang XU, Hong YUE, Tingyao ZHANG, Jiamiao FU, Xinyi HUANG